MedTrace Logo

500mg Fulvestrant Versus Exemestane in MBC

NCT03575260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2019-07-30

No results posted yet for this study

Summary

500mg Fulvestrant versus Exemestane in MBC

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Biyun Wang, Professor · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-01-10
Completion
2019-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575260 on ClinicalTrials.gov